These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1712267)

  • 1. Cilazapril. A review.
    Szucs T
    Drugs; 1991; 41 Suppl 1():18-24. PubMed ID: 1712267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilazapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiovascular disease.
    Deget F; Brogden RN
    Drugs; 1991 May; 41(5):799-820. PubMed ID: 1712710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilazapril: a new non-thiol-containing angiotensin-converting enzyme inhibitor. Worldwide clinical experience in hypertension.
    Kögler P
    Am J Med; 1989 Dec; 87(6B):50S-55S. PubMed ID: 2532461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of cilazapril.
    Kleinbloesem CH; van Brummelen P; Francis RJ; Wiegand UW
    Drugs; 1991; 41 Suppl 1():3-10. PubMed ID: 1712269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of cilazapril.
    Kleinbloesem CH; Van Brummelen P; Francis RJ; Wiegand UW
    Am J Med; 1989 Dec; 87(6B):45S-49S. PubMed ID: 2532460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.
    Natoff IL; Nixon JS; Francis RJ; Klevans LR; Brewster M; Budd J; Patel AT; Wenger J; Worth E
    J Cardiovasc Pharmacol; 1985; 7(3):569-80. PubMed ID: 2410692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cilazapril: an overview of its efficacy and safety in hypertension.
    Szucs T; Schneeweiss A
    Cardiology; 1992; 80(1):34-41. PubMed ID: 1532534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.
    Essig J; Belz GG; Wellstein A
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):217S-223S. PubMed ID: 2548551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and effects on renal function following cilazapril and hydrochlorothiazide alone and in combination in healthy subjects and hypertensive patients.
    Nilsen OG; Sellevold OF; Romfo OS; Smedsrud A; Grynne B; Williams PE; Kleinbloesem CH
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):323S-328S. PubMed ID: 2527546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.
    Waterfall JF
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):139S-150S. PubMed ID: 2527528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol.
    Erb KA; Essig J; Breithaupt K; Belz GG
    Drugs; 1991; 41 Suppl 1():11-7. PubMed ID: 1712266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients.
    Belz GG; Essig J; Erb K; Breithaupt K; Hoogkamer JF; Kneer J; Kleinbloesem CH
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):317S-322S. PubMed ID: 2527545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New, in Austria registered specialty drugs. Inhibace (cilazapril)].
    Töglhofer W
    Wien Klin Wochenschr; 1992; 104(6):178-82. PubMed ID: 1533738
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta-blocker propranolol and their combination on haemodynamics in hypertension.
    Belz GG; Breithaupt K; Erb K; Kleinbloesem CH; Wolf GK
    J Hypertens; 1989 Oct; 7(10):817-24. PubMed ID: 2531184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.
    Kleinbloesem CH; Erb K; Essig J; Breithaupt K; Belz GG
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):309S-315S. PubMed ID: 2527544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects and pharmacokinetics of single and consecutive doses of cilazapril in hypertensive patients with normal or impaired renal function.
    Shionoiri H; Gotoh E; Sugimoto K; Takasaki I; Minamisawa K; Ishii M
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):283S-287S. PubMed ID: 2527540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the combination of cilazapril and propranolol lower blood pressure at rest and during exercise more pronouncedly than either of the two components given alone?
    Erb KA; Breithaupt K; Kleinbloesem CH; Wolf GK; Belz GG
    Clin Physiol Biochem; 1990; 8 Suppl 2():35-45. PubMed ID: 2151315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the acute and chronic effects of cilazapril and hydrochlorothiazide on diastolic cardiac function in hypertensive patients.
    Schneeweiss A; Rosenthal J; Marmor A
    J Hum Hypertens; 1990 Oct; 4(5):535-9. PubMed ID: 2149388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers.
    Wellstein A; Essig J; Belz GG
    Clin Pharmacol Ther; 1987 Jun; 41(6):639-44. PubMed ID: 3034469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.